Effect of N-acetylcystein in Myocardial Infarction
Launched by TEHRAN UNIVERSITY OF MEDICAL SCIENCES · Nov 30, 2012
Trial Information
Current as of May 13, 2025
Unknown status
Keywords
ClinConnect Summary
Percutaneous coronary intervention(PCI) is one of the standard therapies for acute coronary syndrome. Despite major advances in PCI procedure, impaired myocardial perfusion frequently occurred after primary PCI and resulted in a larger infarct size and increased morbidity and mortality.Reperfusion injury process can be resulted in additional death of cardiomyocytes and it is suggested that oxidative stress is a contributing factor to induce reperfusion injury.During PCI,trauma occurs to the arterial endothelium, causes the activation and aggregation of platelets.
It is estimated that appro...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Myocardial infarction patients who were candidate of primary PCI
- Exclusion Criteria:
- • Rescue PCI
- • Emergency for cardiac bypass
- • Cardiogenic shock
- • Life expectancy less than 6 months
- • Age less than 18 years old
- • Uncontrolled hypertension
- • Thrombocytopenia
- • Malformation or aneurysm
- • Sever chronic kidney disease
- • Sever liver failure
- • Major surgery within 3 months
- • Unsatisfactory to enter the study
About Tehran University Of Medical Sciences
Tehran University of Medical Sciences (TUMS) is a prestigious institution dedicated to advancing healthcare through innovative research and education. As a leading clinical trial sponsor, TUMS is committed to conducting high-quality, ethically sound clinical research that contributes to the understanding and treatment of various medical conditions. With a strong emphasis on collaboration and interdisciplinary approaches, TUMS harnesses the expertise of its diverse faculty and state-of-the-art facilities to facilitate groundbreaking studies that aim to improve patient outcomes and enhance public health. Through its rigorous oversight and adherence to regulatory standards, TUMS ensures the integrity and reliability of its clinical trials, fostering trust and transparency in the research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Azita Hajhossein Talasaz, PharmD,BCPS
Principal Investigator
Tehran University of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials